A systematic review of antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease

References

• Eisen A, Krieger C. Amyotrophic lateral sclerosis: a synthesis of research and clinical practice. Cambridge University Press, Cambridge 1998
   Google Scholar
• Logroscino G, Beghi E, Zoccolella S, Palagano R, Fraddosio A, Simone IL, et al. The SLAP Registry. Incidence of amyotrophic lateral sclerosis in southern Italy: a population based study. Journal of Neurology Neurosurgery and Psychiatry. 2005; 76: 1094–8
   PubMed Web of Science ®Google Scholar
• Sejvar JJ, Holman RC, Bresee JS, Kochanek KD, Schonberger LB. Amyotrophic lateral sclerosis mortality in the United States, 1979–2001. Neuroepidemiology. 2005; 25: 144–52
   PubMed Web of Science ®Google Scholar
• Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993; 362: 59–62
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, Guillet P, Menninger V, The ALS/Riluzole Study Group II. A dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347:1425–31.
   Google Scholar
• Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) (Cochrane review). Cochrane Database of Systematic Reviews 2004, Issue 3.
   Google Scholar
• Bergeron C, Petrunka C, Weyer L. Oxidative stress plays a role in the pathogenesis of familial and sporadic amyotrophic lateral sclerosis. Neurodegenerative Diseases, G Fiskum. Plenum Press, New York 1996; 275–80
   Google Scholar
• Sardesai VM. Role of antioxidants in health maintenance. Nutrition in Clinical Practice. 1995; 10: 19–25
   PubMedGoogle Scholar
• Beckman JS, Carson M, Smith CD, Koppenol WH. ALS, SOD and peroxynitrite. Nature. 1993; 364: 584
   PubMed Web of Science ®Google Scholar
• Ince PG, Shaw PJ, Candy JM, Mantle D, Tandon L, Ehmann WD, Markesbery WR. Iron, selenium and glutathione peroxidase activity are elevated in sporadic motor neuron disease. Neuroscience Letters. 1994; 182: 87–90
   PubMed Web of Science ®Google Scholar
• Mitchell JD. Heavy metals and trace elements in amyotrophic lateral sclerosis. Neurology Clinics. 1987; 5: 43–60
   PubMedGoogle Scholar
• Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs and Aging. 2001; 18: 685–716
   PubMed Web of Science ®Google Scholar
• Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Annals of Neurology. 1996; 39: 147–57
   PubMed Web of Science ®Google Scholar
• Knoll J. The pharmacology of selegiline ((−)deprenyl). New aspects. Acta Neurologica Scandinavica. Supplementum. 1989; 126: 83–91
   Google Scholar
• Janik P, Kwiecinski H, Jamrozik Z, Czyzewski K, Opuchlik A. A randomized trial of antioxidative therapy in amyotrophic lateral sclerosis. Journal of Neurology. 1996; 243(Suppl): 25
   Google Scholar
• Jossan SS, Ekblom J, Gudjonsson O, Hagbarth KE, Aquilonius SM. Double-blind crossover trial with deprenyl in amyotrophic lateral sclerosis. Journal of Neural Transmission. 1994; 41(Suppl): 237–41
   Google Scholar
• Lange DJ, Murphy PL, Diamond B, Appel V, Lai EC, Younger DS, et al. Selegiline is ineffective in a collaborative double-blind, placebo controlled trial for treatment of amyotrophic lateral sclerosis. Archives of Neurology. 1998; 55: 93–6
   PubMed Web of Science ®Google Scholar
• Mazzini L, Testa D, Balzarini C, Mora G. An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis. Journal of Neurology. 1994; 241: 223–7
   PubMed Web of Science ®Google Scholar
• Mitchell JD, Gatt JA, Phillips TM, Houghtohn E, Rostron G, Wignall C. Cu/Zn superoxide dismutase free radicals, and motor neuron disease. Lancet. 1993; 342: 1051–2
   PubMed Web of Science ®Google Scholar
• Mitchell JD, Houghton E, Rostron G, Wignall C, Gatt JA, Phillips TM, et al. Serial studies of free radical and antioxidant activity in motor neuron disease and the effect of selegiline. Neurodegeneration. 1995; 4: 233–5
   PubMed Web of Science ®Google Scholar
• Louwerse ES, Weverling GJ, Bosuyt PM, Meyjes FE, de Jong JM. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Archives of Neurology. 1995; 52: 559–64
   PubMed Web of Science ®Google Scholar
• Vyth A, Timmer JG, Bossuyt PMM, Louwerse ES, de Jong JM. Survival in patients with amyotrophic lateral sclerosis treated with an array of antioxidants. Journal of the Neurological Sciences. 1996; 39(Suppl): 99–103
   Google Scholar
• Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial ‘Clinical limits of amyotrophic lateral sclerosis’ workshop contributors. Journal of the Neurological Sciences. 1994; 124(Suppl): 96–107
   PubMed Web of Science ®Google Scholar
• Kwiecinski H, Janik P, Jamrozik Z, Opuchlik A. The effect of selegiline and vitamin E in the treatment of ALS: an open randomized clinical trial (In Polish.). Neurologia i Neurochirurgia Polska. 2001; Suppl 1: 101–6
   Google Scholar
• Szczudilk A, Tomi B, Slowik A, Kasprzyk K. Assessment of the efficacy of treatment with pimozide in patients with amyotrophic lateral sclerosis. Neurologia i Neurochirurgia Polska. 1998; 48: 821–9
   Google Scholar
• Engel WK, Hogenhuis LAH, Collis WJ, Schalch DS, Barlow MH, Gold GN, . Metabolic studies and therapeutic trials in amyotrophic lateral sclerosis. Motor neuron diseases, FH Norris, LT Kurland, et al. Grune and Stratton, New York 1969; 199–208
   Google Scholar
• Stevic Z, Nicolic A, Blagojevic D, Saicic ZS, Apolstolski S, Spasic M. A controlled trial of combination of methionine and antioxidants in amyotrophic lateral sclerosis. In: Proceedings ALS/MND International Alliance Meeting, MunichGermany. 1998.
   Google Scholar
• Dorman JD, Engel WK, Fried DM. Therapeutic trial in amyotrophic lateral sclerosis. JAMA. 1969; 209: 257–8
   PubMed Web of Science ®Google Scholar
• Stevic Z, Nicolic A, Blagjevic D, Saicia ZS, Kocev N, Apostolski S, et al. A controlled trial of combination of methionine and antioxidants in ALS patients. Jugoslavenska Medicinska Biokemija. 2001; 20: 223–8
   Google Scholar
• Mitchell JD, Houghton E, Rostron G, Wignall C, Phillips TM, Kilshaw J. Indices of free radical and antioxidant activity in amyotrophic lateral sclerosis. ALS: from Charcot to the present and into the future, F Clifford Rose. Smith-Gordon and Company Ltd, London 1994; 297–307
   Google Scholar
• Chio A, Cucatto A, Terreni AA, Schiffer D. Reduced glutathione in amyotrophic lateral sclerosis: an open, crossover, randomized trial. Italian Journal of Neurological Science. 1998; 19: 363–6
   PubMedGoogle Scholar
• Quick DT. Pancreatic dysfunction in amyotrophic lateral sclerosis. Motor neuron diseases, FH Norris, LT Kurland. Grune and Stratton, New York 1969; 189–98
   Google Scholar
• Wechsler IS. The treatment of amyotrophic lateral sclerosis with vitamin E (tocopherols). American Journal of Medical Science. 1940; 200: 765–78
   Google Scholar
• Ascherio A, Weisskopf MG, O'Reilly EJ, Jacobs EJ, McCullough ML, Calle EE, et al. Vitamin E intake and risk of amyotrophic lateral sclerosis. Annals of Neurology. 2005; 57: 104–10
   PubMed Web of Science ®Google Scholar
• Apolstolski S, Markinkovic Z, Nocolic A, Blagojevic D, Spasic MB, Michelson AM. Glutathione peroxidase in amyotrophic lateral sclerosis: the effects of selenium supplementation. Journal of Environmental Pathology. Toxicology and Oncology. 1998; 17: 325–9
   PubMedGoogle Scholar
• Desnuelle C, Dib M, Garrel C, Favier A. ALS riluzole-tocopherol study group. A double-blind, placebo controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 2: 9–18
   PubMed Web of Science ®Google Scholar
• Ellis T, Cudkowicz ME, McKenna-Yasek D, Eggelston PM, Brown RH, Cros D. Combination antioxidant therapy in amyotrophic lateral sclerosis. Neurology. 1997; 48: 127
   Web of Science ®Google Scholar
• Graf M, Ecker D, Horowski R, Riederer P, Gerlach M, Hager C, Ludolph AC, on behalf of the German vitamin E/ALS Study Group. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo controlled double-blind study. Journal of Neurotransmission. 2005;112:649–60.
   Google Scholar
• Greenberg ER. Vitamin E supplements: good in theory, but is the theory good?. Annals of Internal Medicine. 2004; 142: 75–6
   PubMedGoogle Scholar
• Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Annals of Internal Medicine. 2004; 142: 37–46
   PubMedGoogle Scholar
• Pioro EP. Antioxidant therapy in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000; 1(Suppl 4)5–12
   PubMedGoogle Scholar
• Norris FH, Denys EH. Nutritional supplements in amyotrophic lateral sclerosis. Advances in Experimental Medicine and Biology. 1987; 209: 183–9
   PubMedGoogle Scholar